US › Healthcare

Immuneering Corp (IMRX)

US · Healthcare · Biotechnology

$3.59-1.37%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$360,958

Net profit

$-17.3M

EPS

$-0.27

EPS estimate

$-0.26

Net margin

-4,784.6%

EPS came in at -0.27 against a street estimate of -0.26 — a miss of 3.8%.

Key statistics

Market cap

$230.3M

Forward P/E

0.0

P/B

1.49

Book value

$2.95

EPS (TTM)

$-0.93

52-week high

$8.48

52-week low

$3.41

50-day MA

$4.59

200-day MA

$4.97

Beta

0.46

Analyst view

Analysts rate Immuneering Corp a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $17.17.

Shareholding

Insiders

13.83%

Institutions

55.44%

Largest institutional holders

Fund	Stake
FMR Inc	15.00%
BlackRock Inc	6.76%
Sanofi	4.19%
Vanguard Capital Management, LLC	3.53%
T. Rowe Price Associates, Inc.	2.99%
Geode Capital Management, LLC	2.12%
State Street Corp	1.55%
DCF Advisers, LLC	1.22%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immuneering Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.